GLP-1 vs. Peptide Therapy for Weight Loss: A Functional Medicine Doctor’s Honest Comparison

By Brian Lamkin, DO | The Lamkin Clinic, Edmond, Oklahoma | Last reviewed May 2026

Quick answer: GLP-1 medications (like Ozempic, Wegovy, Mounjaro, and Zepbound) and peptide therapy are not the same thing. GLP-1 drugs are pharmaceuticals that suppress appetite by mimicking a gut hormone. Therapeutic peptides such as MOTS-c work differently, by supporting the body’s own metabolic processes at the cellular level. GLP-1 medications reliably produce weight loss but require ongoing use, and most patients regain about two-thirds of the lost weight within a year of stopping. Peptide therapy targets underlying drivers like insulin resistance and mitochondrial function. The right choice depends on what is actually driving your weight gain, which is why a functional medicine workup comes before any prescription.

Every week, patients ask me a version of the same question. “What do you think about Ozempic?” Or the inverse: “I’ve been reading about peptides for weight loss. Is that the same thing as a GLP-1?”

They are not the same thing. They work through different mechanisms, carry different risk profiles, and serve different patient needs. Understanding that distinction is one of the most useful things you can do before starting any weight loss protocol.

Here is my honest clinical perspective, based on more than 25 years of practice and treating over 1,500 patients here at The Lamkin Clinic in Edmond.

How Do GLP-1 Medications Work?

GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), are pharmaceutical drugs that mimic a naturally occurring gut hormone called glucagon-like peptide-1. That hormone slows gastric emptying, dampens appetite, and prompts insulin release in response to food. The clinical result is significant caloric restriction and, in well-designed trials, substantial weight reduction.

This is real. The STEP trials showed semaglutide producing roughly 15 to 17 percent body weight reductions in adults with obesity over 68 weeks. No serious clinician disputes the numbers.

But “it works” and “it is the right tool for you” are two very different questions.

What Are the Real Limitations of GLP-1 Drugs?

The core issue with GLP-1 therapy for many patients is that it suppresses appetite without addressing the metabolic dysfunction driving weight gain in the first place. That distinction has real clinical consequences.

The weight comes back when the medication stops

In the STEP 1 trial extension, published in Diabetes, Obesity and Metabolism (Wilding et al., 2022), patients who discontinued semaglutide regained about two-thirds of their lost weight within one year. Multiple reviews through 2025 and 2026 have confirmed this pattern broadly: stopping treatment tends to lead to rapid, clinically significant weight regain. These medications were designed for long-term, often lifelong, use. For many patients, that is neither feasible nor what they want.

Lean muscle loss is a genuine tradeoff

Research consistently shows that roughly 25 to 40 percent of the weight lost on GLP-1 medications is lean body mass, not fat. A 2025 Endocrine Society presentation put the figure near 40 percent for semaglutide, and a 2024 Circulation clinical primer reported a similar range across the drug class.

For patients over 40 who are already losing muscle through natural aging, this matters. Less muscle means a slower resting metabolic rate, which makes keeping weight off harder over time. It also compounds the risk of functional decline and bone density loss, which is the opposite of what a longevity-focused patient is working toward.

Here is the important nuance: this loss is manageable. Newer data, including the 2025 SEMALEAN study, shows that lean mass can be largely preserved when adequate protein, resistance training, and body composition monitoring are built into the protocol. The problem is not the medication alone. The problem is prescribing it without a plan to protect muscle.

The root causes go unaddressed

Insulin resistance, sex hormone decline (testosterone, estrogen, progesterone), thyroid dysfunction, mitochondrial inefficiency, and chronic inflammation all drive weight gain through mechanisms that appetite suppression does not touch. A patient can lose 30 pounds on semaglutide and still carry the same underlying metabolic dysfunction they started with. When the drug stops, the biology reasserts itself.

For the right patient, GLP-1 medications absolutely have a place. For many patients seeking medical weight loss in Edmond and the Oklahoma City area, building a protocol on appetite suppression alone sets them up for a cycle of medication dependence with no durable resolution.

What Does Peptide Therapy Offer?

Peptides are short chains of amino acids that act as biological signaling molecules. Unlike GLP-1 receptor agonists, which are synthetic pharmaceutical drugs, the therapeutic peptides used in functional medicine work by supporting the body’s own physiological processes rather than overriding them.

Two categories are most relevant to weight loss and metabolic health.

MOTS-c

MOTS-c is a mitochondrial-derived peptide. In the landmark study that introduced it, published in Cell Metabolism (Lee et al., 2015), researchers showed that MOTS-c regulates insulin sensitivity and metabolic homeostasis through the AMPK pathway, and that treatment prevented diet-induced obesity and insulin resistance in animal models. Endogenous MOTS-c levels also decline with age, which helps explain why metabolic efficiency tends to drop in our 40s and 50s regardless of diet or exercise.

A point of honesty: much of the foundational metabolic research on MOTS-c is preclinical, meaning it comes from animal and laboratory studies, with human clinical data still developing. I think patients deserve to know that rather than be sold certainty that does not yet exist. What the science supports is a clear mechanism for supporting mitochondrial function and insulin sensitivity, which is why MOTS-c therapy is a thoughtful tool for patients whose weight loss resistance traces back to metabolic and mitochondrial dysfunction, without artificially suppressing appetite.

CJC-1295 and Ipamorelin

CJC-1295 and Ipamorelin are growth hormone-releasing peptides that stimulate the pituitary gland’s own GH production. Used together, they support fat metabolism, lean muscle preservation, and better sleep quality, since growth hormone peaks during deep sleep. For patients concerned about body composition during weight loss, this combination integrates well with a structured metabolic protocol.

Peptide therapy is not a shortcut. It is a tool that works best once a patient’s full metabolic picture is understood.

GLP-1 Medications vs. Peptide Therapy at a Glance

In some cases, the most effective protocol uses elements of both, alongside hormone optimization.

The Functional Medicine Approach to Medical Weight Loss

When a patient comes to The Lamkin Clinic in Edmond for medical weight loss, we do not start with a prescription. We start with a question: why is your metabolism not working the way it should?

Answering that requires comprehensive lab work. A standard weight loss workup at our clinic includes:

• Fasting insulin and HOMA-IR, a direct measure of insulin resistance
• Hemoglobin A1C
• A full thyroid panel, including Free T3, Free T4, and Reverse T3 (not just TSH)
• Comprehensive sex hormone panels for both men and women
• Cortisol patterns
• Inflammatory markers
• Advanced lipid particle analysis
• A DEXA body composition scan to precisely measure fat mass, lean mass, visceral fat, and bone mineral density

That diagnostic picture determines the protocol.

Some patients have severe insulin resistance that responds well to MOTS-c combined with targeted dietary changes. Some have low testosterone or an estrogen imbalance that has been quietly sabotaging body composition for years, and hormone optimization is the right first step. Some have thyroid dysfunction that no conventional lab caught because only TSH was tested. Others are good candidates for a carefully supervised GLP-1 protocol, integrated with peptide therapy and hormone support to protect lean mass and long-term metabolic function.

The right answer is individual. That is the heart of functional medicine: the protocol fits the patient, not the other way around. Prescribing the same medication to everyone who wants to lose weight, regardless of their biology, is not a functional medicine approach.

So Which Is Right for You?

There is no universal answer, and any clinician who hands you one is not serving your best interest.

GLP-1 medications are powerful pharmaceutical tools with legitimate clinical applications. Peptide therapy is a sophisticated biological intervention with a distinct mechanism and a meaningful role in functional medicine-based weight loss. Both have their place in the right context, and sometimes the best protocol draws on both.

What matters is whether your protocol is built on three things: understanding your actual metabolic drivers, protecting your lean mass and long-term health, and producing results that hold after treatment ends.

If you are in the Edmond or Oklahoma City area and ready to find out what is actually driving your weight gain, we are ready to help you build a protocol designed around your biology.

Frequently Asked Questions

Is peptide therapy the same as a GLP-1 like Ozempic? No. GLP-1 medications are synthetic pharmaceutical drugs that suppress appetite by mimicking a gut hormone. Therapeutic peptides such as MOTS-c are signaling molecules that support the body’s own metabolic and cellular processes. They work through entirely different mechanisms.

Do you regain weight after stopping Ozempic or Wegovy? Usually, yes. In the STEP 1 trial extension, patients regained about two-thirds of their lost weight within one year of stopping semaglutide. These medications are designed for long-term use, and weight tends to return once they are discontinued unless the underlying metabolic drivers have also been addressed.

Does Ozempic cause muscle loss? Roughly 25 to 40 percent of the weight lost on GLP-1 medications can come from lean body mass, including muscle, if it is not actively managed. With adequate protein, resistance training, and body composition monitoring, that loss can be substantially reduced. This is one reason GLP-1 therapy is best supervised rather than prescribed in isolation.

What is MOTS-c and how does it help with weight loss? MOTS-c is a mitochondrial-derived peptide that supports insulin sensitivity and metabolic function at the cellular level. Its levels decline with age, which may contribute to slower metabolism over time. Much of the metabolic research is still preclinical, but the mechanism makes it a useful tool for patients whose weight loss resistance is rooted in insulin resistance or mitochondrial inefficiency.

Can you combine GLP-1 medications with peptide therapy? Yes. For some patients, the most effective approach combines a supervised GLP-1 protocol with peptide therapy and hormone optimization to drive fat loss while protecting lean mass and addressing root causes.

Where can I get medical weight loss in Edmond, Oklahoma? The Lamkin Clinic in Edmond serves patients across the Oklahoma City metro with individualized, lab-based weight loss protocols. Every plan begins with comprehensive testing rather than a one-size-fits-all prescription.

Ready to Take a Real Look at Your Metabolism?

Schedule a Medical Weight Loss consultation at The Lamkin Clinic. Dr. Brian Lamkin, DO will review your history, evaluate the right labs, and build a protocol that fits your physiology, not a one-size-fits-all trend.

Request an appointment at lamkinclinic.com/contact

About the Author

Dr. Brian Lamkin is the founder and physician of The Lamkin Clinic with over 25 years of clinical experience, a functional and regenerative medicine practice in Edmond, Oklahoma, serving patients across the Oklahoma City metro. Founded in 2007, the clinic offers individualized protocols in hormone optimization, peptide therapy, medical weight loss, longevity medicine, and BTL body and aesthetic technology.

This article is for educational purposes and is not a substitute for individualized medical advice. Treatment decisions should be made with a qualified clinician who has evaluated your specific labs and history.